Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
MELBOURNE, Australia, Sept. 05, 2017 -- Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX:CYP), announced today it will be featured as a presenting company at the 19th Annual Rodman & Renshaw Global Investment Conference. The conference is being held on September 10-12, 2017 in New York City.
The Rodman & Renshaw conference is sponsored by H. C. Wainwright & Co., a leading Wall Street investment bank, with a strong reputation in life sciences. Over 2,000 institutional and other investors are expected to attend the conference, each with a significant interest in the life sciences sector.
Dr Ross Macdonald, Managing Director and CEO, will provide an overview of the Company and its unique Cymerus™ platform during the live presentation and will also be participating in one-on-one meetings with U.S. and international investors and potential partners who are registered to attend the conference. A copy of the presentation will be made available on Cynata’s website.
If you are an institutional investor, and would like to attend the Company’s presentation, please visit the Rodman & Renshaw website to register for the conference. Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Company.
Event: 19th Annual Rodman & Renshaw Global Investment Conference
Date: September 11, 2017
Time: 3:00pm (US Eastern Time)
Location: Holmes II Room; Lotte New York Palace Hotel in New York City
About Cynata Therapeutics (ASX:CYP)
Cynata Therapeutics Limited (ASX:CYP) is an Australian clinical-stage stem cell and regenerative medicine company developing therapies based on its proprietary Cymerus™ stem cell technology platform. Cymerus overcomes critical issues in the production of therapeutic mesenchymal stem cells (MSCs) by enabling the economical manufacture of commercial-scale MSCs, independent of multi-donor limitations. Cymerus’ novel approach utilises induced pluripotent stem cells (iPSCs) derived from a single blood donation to generate mesenchymoangioblasts (MCAs), a precursor that is used to manufacture an unlimited number of therapeutic MSCs. Cynata’s unique “off-the-shelf” Cymerus platform has the potential to create a new standard in the development and manufacture of stem cell therapeutics.
CONTACTS: Dr Ross Macdonald, CEO, 0412 119343, [email protected] Daniel Paproth, Australia Media Contact, 0421 858 982, [email protected] Laura Bagby, U.S. Media Contact, 312-448-8098, [email protected]
